Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Holdings Boosted by XTX Topco Ltd

XTX Topco Ltd raised its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 969.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 233,597 shares of the company's stock after purchasing an additional 211,759 shares during the quarter. XTX Topco Ltd owned about 0.14% of Neumora Therapeutics worth $234,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in NMRA. PEAK6 LLC acquired a new position in Neumora Therapeutics in the fourth quarter valued at $117,000. Rafferty Asset Management LLC acquired a new position in shares of Neumora Therapeutics in the 4th quarter valued at about $185,000. BNP Paribas Financial Markets acquired a new stake in Neumora Therapeutics during the 4th quarter worth approximately $221,000. CWM LLC raised its holdings in Neumora Therapeutics by 7,124.4% in the first quarter. CWM LLC now owns 25,213 shares of the company's stock valued at $25,000 after buying an additional 24,864 shares during the period. Finally, Janus Henderson Group PLC acquired a new position in Neumora Therapeutics during the fourth quarter valued at approximately $281,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Stock Up 3.2%

Neumora Therapeutics stock traded up $0.05 during midday trading on Friday, hitting $1.63. 888,869 shares of the stock were exchanged, compared to its average volume of 1,668,445. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.54 and a quick ratio of 10.54. The company has a 50 day moving average price of $1.31 and a two-hundred day moving average price of $1.17. The firm has a market cap of $263.97 million, a P/E ratio of -1.04 and a beta of 2.91. Neumora Therapeutics, Inc. has a 1 year low of $0.61 and a 1 year high of $17.19.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.05. On average, sell-side analysts predict that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on NMRA. Needham & Company LLC reissued a "buy" rating and issued a $5.00 target price on shares of Neumora Therapeutics in a research note on Tuesday, May 13th. Mizuho raised their price objective on Neumora Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Neumora Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $7.14.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.